Recently, the 2025 GBC Global Biomanufacturing Conference was held in Suzhou, China, where the 2025 Biomanufacturing Industry Rankings were officially released. Leveraging its strong capabilities in original R&D, full industry-chain integration, and sustainable growth, Leadsynbio was honored as one of the “Top 10 Future Pharma in Biomanufacturing 2025.”

As an early pioneer in China’s biomanufacturing sector, Leadsynbio has established an advanced synthetic biology R&D platform and a vertically integrated supply chain. By continuously driving technology innovation, the company has successfully developed several first-in-class biosynthetic processes, enabling large-scale and stable supply of core products. These solutions provide cost-effective and environmentally friendly alternatives across intermediate APIs, human nutrition, and animal nutrition.

Today, Leadsynbio is recognized as one of China’s leading producers of Florfenicol API and 25-Hydroxyvitamin D3 (25-OH-D3). Its products are exported to over 20 countries and regions, including the United States, Germany, Japan, Singapore, India, Brazil, and Pakistan, gaining increasing global recognition and market influence.

This selection not only affirms Leadsynbio’s comprehensive strength in biomanufacturing but also highlights its strong growth potential. Moving forward, the company will continue to deepen its presence in biomanufacturing, further strengthen original innovation and industrialization capacity, and expand its product portfolio and service offerings—contributing to the sustainable innovation of the global biomanufacturing industry.